In addition to EGFR mutations, patients with NSCLC may harbor other molecular/genetic aberrations that can be targeted by targeted therapies, such as neurotrophic tropomyosin receptor kinase (NTRK), anaplastic lymphoma kinase (ALK), BRAF, and ROS1 [97,98]. Here, ALK is linked to non-small cell lung carcinoma.